Nucleic acid therapeutics are driving the third wave of innovation in modern drug development, a view that has become widely recognized across the industry. The global nucleic acid therapeutics market continues to grow rapidly, with applications expanding from rare diseases to chronic conditions such as hyperlipidaemia and hypertension. In terms of technology development, extrahepatic delivery has become an important direction for next-generation breakthroughs.

In China, the number of approved IND applications for oligonucleotide therapeutics has increased significantly, covering multiple disease areas including cardiovascular and infectious diseases. Companies such as Alnylam Pharmaceuticals have achieved early clinical progress in neurodegenerative diseases including Alzheimer’s disease, while siRNA therapeutics for lipid lowering and blood pressure reduction are also accelerating into clinical development in China. Each technological breakthrough continues to reshape traditional therapeutic approaches.

The inaugural China Pharmaceutical Innovation Conference (CPIC), organized by TONACEA, will be held from July 22 to 24, 2026 at the National Exhibition and Convention Center (Shanghai).

As a leading nonclinical CRO affiliated with Sinopharm Group, InnoStar will co-host a dedicated conference session on nucleic acid therapeutics together with Tofflon and GemPharmatech. The session aims to bring together leading scientists, industry leaders, and clinical experts in the field of nucleic acid therapeutics to conduct in-depth discussions on delivery technology breakthroughs, CMC process development, nonclinical evaluation, and industrial application.

CPIC is benchmarked against the J.P. Morgan Healthcare Conference in the United States and is committed to building a new model of “China Innovation, Global Collaboration, and Shanghai Transactions.” The conference aims to serve as an important platform for overseas capital and enterprises to better understand China’s innovation ecosystem, while also supporting Chinese pharmaceutical companies in global expansion and international collaboration. The annual event is expected to become a key platform for investment and cooperation in the healthcare industry.

InnoStar: Supporting Nucleic Acid Therapeutics from Laboratory Research to Global Regulatory Submission

In the field of nucleic acid therapeutics, InnoStar has supported more than 100 nucleic acid drug projects with extensive service experience and strong regulatory submission capabilities. These projects include IND submission studies, NDA submission studies, as well as non-registration studies covering early-stage screening, pharmacology, and pharmacokinetic research.

Representative projects include a lipid-lowering siRNA therapeutic with concurrent IND filings in China, the United States, and Australia, as well as China’s first out-licensed cardiovascular siRNA program.

From July 22 to 24, InnoStar looks forward to joining industry partners at the National Exhibition and Convention Center (Shanghai) to support innovation in the nucleic acid therapeutics industry and promote the global development of China’s pharmaceutical innovation.

Conference Information

Conference: CPIC 2026
Date: July 22–24, 2026
Location: National Exhibition and Convention Center (Shanghai)